Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.69 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.69 |
| ▸ | HTR1A | P08908 | 11/20 | 0.57 |
| ▸ | TNKS | O95271 | 1/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.55 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23302863 | 1.00 | PARP1 (0.69) | PARP1PARP2HTR1ATNKSTNKS2 | |
| SCHEMBL29786850 | 0.88 | PARP1 (0.54) | PARP1PARP2HTR1ATNKSTNKS2 | |
| SCHEMBL29882260 | 0.88 | PARP1 (0.57) | PARP1PARP2HTR1A | |
| SCHEMBL23302454 | 0.88 | PARP1 (0.57) | PARP1PARP2HTR1A | |
| SCHEMBL23302521 | 0.88 | PARP1 (0.54) | PARP1PARP2HTR1ATNKSTNKS2 | |
| SCHEMBL23320305 | 0.87 | PARP1 (0.64) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL29882308 | 0.85 | DRD2 (0.55) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL23303646 | 0.85 | PARP1 (0.51) | PARP1PARP2HTR1ATNKSTNKS2 | |
| SCHEMBL29786983 | 0.85 | PARP1 (0.51) | PARP1PARP2HTR1ATNKSTNKS2 | |
| SCHEMBL23302482 | 0.84 | PARP1 (0.50) | PARP1PARP2HTR1ATNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929673-A | Isoquinolinone derivatives, preparation method thereof, and pharmaceutical composition for preventing or treating poly (ADP-ribose) polymerase 1(PARP-1) -related diseases comprising the same as active ingredient | 多临生物株式会社 | 2022-08-19 | — | — | CN | claimed |
| US-12459899-B2 | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient | DIGMBIO, Inc. (KR) | 2025-11-04 | — | — | US | disclosed |
| US-20230027362-A1 | ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT | DIGMBIO. INC. (KR) | 2023-01-26 | — | — | US | disclosed |
| CN-114929673-A | Isoquinolinone derivatives, preparation method thereof, and pharmaceutical composition for preventing or treating poly (ADP-ribose) polymerase 1(PARP-1) -related diseases comprising the same as active ingredient | 多临生物株式会社 | 2022-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459899-B2 | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885HTR1A 1094/4885 |
| US-20230027362-A1 | ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885HTR1A 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.